Xencor (NASDAQ:XNCR) Reaches New 12-Month High – Still a Buy?

by · The Markets Daily

Xencor, Inc. (NASDAQ:XNCR – Get Free Report) reached a new 52-week high during trading on Monday. The stock traded as high as $33.06 and last traded at $33.0590, with a volume of 1,885,825 shares. The stock had previously closed at $25.18.

Wall Street Analyst Weigh In

XNCR has been the subject of several research reports. Bank of America lifted their target price on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research report on Monday, September 21st. Raymond James Financial raised their target price on Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, September 1st. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Barclays upped their price target on shares of Xencor from $27.00 to $35.00 and gave the company an “overweight” rating in a research report on Friday, September 11th. Finally, Truist Financial restated a “buy” rating and set a $29.00 price objective (up from $27.00) on shares of Xencor in a research report on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average price target of $34.00.

Read Our Latest Report on Xencor

Xencor Trading Up 17.9%

The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -14.64 and a beta of 0.89. The stock’s 50-day moving average is $25.37 and its 200-day moving average is $18.43.

Xencor (NASDAQ:XNCR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.41) EPS. On average, equities analysts predict that Xencor, Inc. will post -3.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of XNCR. GAMMA Investing LLC lifted its holdings in Xencor by 15.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 572 shares during the last quarter. Allworth Financial LP boosted its holdings in Xencor by 23.2% in the 2nd quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 646 shares in the last quarter. WINTON GROUP Ltd lifted its holdings in Xencor by 1.5% in the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after acquiring an additional 1,534 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Xencor in the second quarter valued at about $30,000. Finally, Velan Capital Investment Management LP increased its position in shares of Xencor by 2.0% in the second quarter. Velan Capital Investment Management LP now owns 255,000 shares of the biopharmaceutical company’s stock valued at $4,106,000 after buying an additional 5,000 shares in the last quarter.

Xencor Company Profile

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.

Further Reading